Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men

Obesity

Volumn 18, Issue 12, 2010, Pages 2295-2300

  Gross, Coleman ^a   Blasey, Christine M ^a,b   Roe, Robert L ^a   Belanoff, Joseph K ^a  

^a Corcept Therapeutics Incorporated ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR; HORMONE ANTAGONIST; INSULIN; MIFEPRISTONE; NEUROLEPTIC AGENT; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HORMONE ANTAGONISTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN; MALE; METABOLIC SYNDROME X; MIFEPRISTONE; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; REFERENCE VALUES; RISPERIDONE; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT GAIN; YOUNG ADULT;

EID: 78649938062     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.51     Document Type: Article

References (43)

1. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
2. Baptista T, De Mendoza S, Beaulieu S, Bermúdez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2004;2:290-307.
3. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1): 1-93.
4. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol (Oxford) 2005;19:16-27.
5. Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.
6. Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatric News 2003; 38.
7. American Diabetes Association. Consensus Statement. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596-601.
8. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009;60:1175-1181.
9. Carmel H, Gorman JM. Classifying antipsychotics by likelihood of metabolic side-effects. Psychiatr Serv 2009;60:1143.
10. Baptista T, ElFakih Y, Uzcátegui E et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008;22:477-495.
11. Barnett AH, Mackin P, Chaudhry I et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol (Oxford) 2007;21:357-373.
12. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773.
13. Varley CK, McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009;302:1811-1812.
14. McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008;162:929-935.
15. Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-163.
16. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145-155.
17. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
18. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
19. Ray WA, Chung C P, Murray K T, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360: 225-235.
20. Penzner JB, Dudas M, Saito E et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 2009;19:563-573.
21. Gross C, Blasey CM, Roe RL et al. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009;26:959-969.
22. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51:502-511.
23. Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 2006;171:225-229.
24. Belanoff JK, Blasey CM, Clark R, Roe RL. Selective glucocorticoid receptor (type ii)-antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obes Metab, in press.
25. Johnsen E, Jørgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008;8:31.
26. Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry 2008;20: 71-78.
27. Gopalan C, Rama Sastri B V, Balasubramanian SC et al. Nutritive Value of Indian Foods. National Institute of Nutrition (ICMR): Hyderabad, 2004, p 156.
28. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates: New York, 1988.
29. Reynolds G P, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain-mechanisms and genetics. J Psychopharmacol (Oxford) 2006;20:15-18.
30. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35.
31. Tschoner A, Engl J, Rettenbacher M et al. Effects of six second generation antipsychotics on body weight and metabolism-risk assessment and results from a prospective study. Pharmacopsychiatry 2009;42:29-34.
32. Sowell M, Mukhopadhyay N, Cavazzoni P et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-5880.
33. van Nimwegen LJ, Storosum JG, Blumer RM et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008;93:572-577.
34. Tulipano G, Rizzetti C, Bianchi I et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary- adrenal axis activation. Neuroendocrinology 2007;85:61-70.
35. Tomlinson J, Stewart P. 11β-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome. Drug Discov Today Ther Strateg 2005;2:93-96.
36. Stubbs RJ, Johnstone AM, O'Reilly LM, Poppitt SD. Methodological issues relating to the measurement of food, energy and nutrient intake in human laboratory-based studies. Proc Nutr Soc 1998;57:357-372.
37. Wiklund P, Toss F, Weinehall L et al. Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. J Clin Endocrinol Metab 2008;93:4360-4366.
38. Marques MD, Santos RD, Parga JR et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis, in press.
39. Bobes J, Arango C, Aranda P et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90:162-173.
40. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28.
41. Thomas P, Srivastava V, Singh A et al. Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry Res 2008;161:275-283.
42. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007;68:1793-1798.
43. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009;166:639-641.